GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Stock Based Compensation

BioNTech SE (BSP:B1NT34) Stock Based Compensation : R$656 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Stock Based Compensation?

BioNTech SE's Stock Based Compensation for the three months ended in Mar. 2025 was R$138 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was R$656 Mil.

BioNTech SE Stock Based Compensation Historical Data

The historical data trend for BioNTech SE's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Stock Based Compensation Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 200.91 599.99 603.44 274.65 644.60

BioNTech SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.23 117.11 251.38 150.13 137.57

BioNTech SE Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$656 Mil.

BioNTech SE Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Stock Based Compensation
Comparable Companies
ONC SMMT RPRX INCY INSM EXEL BMRN MRNA ASND ALNY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 OCSE:GMAB XKRX:196170 HKSE:02269
Traded in Other Exchanges
BNTX:USA BNTX:Mexico 22UAd:UK 0A3M:UK 22UA:Germany BNTX:Austria
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
Website
https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

BioNTech SE Headlines

No Headlines